AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.